Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Subscribe To Our Newsletter & Stay Updated
